Volume 21, Number 1—January 2015
Online Report
Workshop on Use of Intravenous Immunoglobulin in Hand, Foot and Mouth Disease in Southeast Asia
Table 1
Absolute risk of progression, IVIg group | Absolute risk increase for placebo group compared with IVIg |
|||
---|---|---|---|---|
+5% | +7.5% | +10% | +15% | |
15% | 2,424 | 1,136 | 670 | 322 |
20% | 2,928 | 1,350 | 784 | 370 |
*Sample sizes are total sample sizes (i.e., for both groups combined) but do not account for loss-to-follow-up or increases in sample size that would be required if formal interim analyses with stopping boundaries are planned. IVIg, intravenous immunoglobulin.
Page created: December 10, 2014
Page updated: December 10, 2014
Page reviewed: December 10, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.